Cardiac Stem Cell Therapy Company, Cardio3 BioSciences, Appoints Former New Jersey Medical School Assistant Professor, Dr. Vinciane Gaussin, as its Chief Scientific Officer (CSO): "The addition of Dr. Gaussin to our management team represents an important milestone in our mission to position Cardio3 BioSciences as a global leader in the field of regenerative therapies for heart failure." - Christian Homsy, MD, CEO, Cardio3 BioSciences

Share Article

Cardio3 BioSciences (http://www.cardio3bio.com) announced today the appointment of Vinciane Gaussin, Ph.D., as its Chief Scientific Officer (CSO), effective immediately.

The addition of Dr. Gaussin to our management team represents an important milestone in our mission to position Cardio3 BioSciences as a global leader in the field of regenerative therapies for heart failure

    Most recently, Dr. Gaussin was an Assistant Professor in the Department of Cell Biology and Molecular Medicine at the University of Medicine and Dentistry of New Jersey (UMDNJ) since 2000. In 2000, she was the second-place finalist for the American Heart Association's prestigious Louis N. and Arnold M. Katz Basic Science Research Prize for Young Investigators. From 1997-1999, Dr. Gaussin was a postdoctoral fellow focusing on developmental biology of the heart at Baylor College of Medicine. She has authored or co-authored 24 clinical basic science research papers in such esteemed journals as Biochemistry Journal, Nature Medicine, Proceedings of the National Academy of Sciences, Circulation and Developmental Biology.

"The addition of Dr. Gaussin to our management team represents an important milestone in our mission to position Cardio3 BioSciences as a global leader in the field of regenerative therapies for heart failure," said Christian Homsy, M.D., CEO of Cardio3 BioSciences. "Over 20 million people worldwide suffer from chronic heart failure, but in spite of the aggressive approaches used to treat heart patients, no effective means are available to repair a damaged heart--yet. Fortunately, the regenerative potential of stem cells guided toward a cardiac lineage are expected to change this scenario, and we are looking forward with great anticipation to our first-in-man procedure scheduled for the first half of next year."

In June, the Company announced that it has entered into a collaborative agreement with Mayo Clinic related to the licensing of Mayo Clinic research, know-how and intellectual property in the field of cardiac commitment of stem cells. The research, headed by Prof. Andre Terzic and Dr. Atta Behfar at Mayo Clinic, has focused on the guided commitment of adult as well as embryonic stem cells. The scope of the license covers heart failure of ischemic and non-ischemic origin.

Cardio3 BioSciences is a biotechnology company focused on regenerating heart muscle via cardiac lineage-committed stem cell therapy for patients with Congestive Heart Failure (CHF). The Company's first two products, C-Cure(TM) and C-Cath(TM), are a 'complete solution' drug/device combination: C-Cure(TM) is the first biotherapeutic designed from autologous stem cells committed to a cardiac lineage before implantation, developed in collaboration with Mayo Clinic Molecular Biology Group researchers; C-Cath(TM) is a proprietary catheter that allows for the accurate transmyocardial injection of C-Cure(TM).

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ronald Trahan
Visit website